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Abstract
BACKGROUND—Solid organ transplantation recipients have elevated cancer incidence. 
Estimates of absolute cancer risk after transplantation can inform prevention and screening.
METHODS—The Transplant Cancer Match Study links the US transplantation registry with 14 
state/regional cancer registries. The authors used nonparametric competing risk methods to 
estimate the cumulative incidence of cancer after transplantation for 2 periods (1987–1999 and 
2000–2008). For recipients from 2000 to 2008, the 5-year cumulative incidence, stratified by 
organ, sex, and age at transplantation, was estimated for 6 preventable or screen-detectable 
cancers. For comparison, the 5-year cumulative incidence was calculated for the same cancers in 
the general population at representative ages using Surveillance, Epidemiology, and End Results 
data.
RESULTS—Among 164,156 recipients, 8520 incident cancers were identified. The absolute 
cancer risk was slightly higher for recipients during the period from 2000 to 2008 than during the 
period from 1987 to 1999 (5-year cumulative incidence: 4.4% vs 4.2%; P =.006); this difference 
arose from the decreasing risk of competing events (5-year cumulative incidence of death, graft 
failure, or retransplantation: 26.6% vs 31.9%; P <.001). From 2000 to 2008, the 5-year cumulative 
incidence of non-Hodgkin lymphoma was highest at extremes of age, especially in thoracic organ 
recipients (ages 0–34 years: range, 1.74%–3.28%; aged >50 years; range, 0.36%–2.22%). For 
recipients aged >50 years, the 5-year cumulative incidence was higher for colorectal cancer 
(range, 0.33%–1.94%) than for the general population at the recommended screening age (aged 50 
years: range, 0.25%–0.33%). For recipients aged >50 years, the 5-year cumulative incidence was 
high for lung cancer among thoracic organ recipients (range, 1.16%–3.87%) and for kidney cancer 
among kidney recipients (range, 0.53%–0.84%). The 5-year cumulative incidence for prostate 
cancer and breast cancer was similar or lower in transplantation recipients than at the 
recommended ages of screening in the general population.
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CONCLUSIONS—Subgroups of transplantation recipients have a high absolute risk of some 
cancers and may benefit from targeted prevention or screening.
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INTRODUCTION
From the beginning of successful solid-organ transplantation, an increased risk of cancer 
after transplantation has been noted.1 This elevated risk arises from several factors, 
including immunosuppression resulting from medications that prevent rejection, decreased 
control of oncogenic viral infections, and underlying medical conditions that are common in 
transplantation recipients. The importance of cancer after transplantation has increased as 
the life expectancy of transplantation recipients has improved. Among kidney, liver, and 
lung recipients, respectively, cancer is now the third, second, and fourth most common cause 
of death 5 years after transplantation.2
Although prior studies have demonstrated an elevated risk for cancer among transplantation 
recipients, most of these studies have not described cancer risk in absolute terms. Absolute 
risk, also called cumulative incidence, is the probability of a transplantation recipient 
developing a given cancer over a specified time interval and depends on both the risk of 
cancer and the risk of competing events (eg death, graft failure).3,4 Absolute risk can be used 
to estimate how many cancers are expected to develop in a population, which can inform 
evidence-based treatment guidelines.5 For example, information about the absolute risk of 
cancer among transplantation recipients could help frame the benefits and costs of cancer 
screening relative to other populations for whom screening is recommended or relative to 
other health needs.
The current study was designed to quantify the absolute risk of cancer after transplantation 
for those cancers that are potentially preventable or detectable by screening. We focused on 
cancers that were common malignancies in US transplantation recipients6 and where there 
are established or proposed approaches for prevention or screening. The 6 cancers that met 
these criteria were non-Hodgkin lymphoma (NHL), lung cancer, colorectal cancer, kidney 
cancer, prostate cancer, and breast cancer. Quantifying the absolute risk of these 
malignancies and identifying subgroups at highest risk may inform screening and treatment 
protocols for solid-organ recipients.
MATERIALS AND METHODS
The Transplant Cancer Match Study links data from the Scientific Registry of Transplant 
Recipients (1987–2008) with 14 population-based US cancer registries (information 
available at: http://transplantmatch.cancer.gov/ [accessed March 7, 2013]).6 Participating 
cancer registries, which together cover approximately 43% of the US transplantation 
population, ascertained the occurrence of malignancies based on mandatory reporting from 
hospitals, medical providers, and pathology laboratories. The study was approved by human 
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subjects committees at the National Cancer Institute and, as required, at participating cancer 
registries.
In the current study, we included kidney, liver, heart, and lung recipients for whom cancer 
registry coverage was present beginning on the transplantation date. We used the linked 
cancer registry data to identify incident cancers after transplantation. Only first cancers after 
transplantation were counted. Although basal cell and squamous cell skin cancers are 
common in transplantation recipients, cancer registries do not capture these cancers, so we 
could not evaluate them in this study.
We used cumulative incidence estimates to assess the absolute risk of cancer after 
transplantation in 2 eras (1987–1999 and 2000–2008) defined by year of transplantation. 
Follow-up time for cumulative incidence computation started at transplantation and ended at 
the earliest of any first cancer, a competing event (death, graft failure, or retransplantation), 
or censoring because of loss to follow-up or end of cancer registry coverage. To avoid 
including prevalent cancers that were present before transplantation, liver and lung cancers 
that were recorded in cancer registries within 6 months of liver or lung transplantation, 
respectively, were not considered as events, and recipients were censored at the time of 
these diagnoses.
To estimate cumulative incidence for cancer overall and for the combined competing events, 
we used the non-parametric methods described by Coviello and Boggess stratified by era.7 
A change across eras in the cumulative incidence of cancer could have 2 possible 
explanations: 1) the hazard (instantaneous risk) of cancer could have changed, or 2) the 
hazard of the competing events could have changed. In other words, the cumulative 
incidence of cancer depends directly on the hazard of cancer (ie, the rate of developing 
cancer among individuals at risk of cancer) and indirectly on the hazard of competing events 
(because this hazard determines who remains at risk of cancer); a decrease in the hazard of 
competing events translates to an increase in the time at risk available for recipients to 
develop cancer. To distinguish between these 2 scenarios, we calculated the hazard ratio 
(HR) (1987–1999 vs 2000–2008) for cancer and the HR (1987–1999 vs 2000–2008) for the 
competing events using Cox proportional hazards models.
Subsequent analyses were restricted to organ transplantations after January 1, 2000, to focus 
on the most recent period and derive results that would be directly applicable to recent 
recipients. For this recent period, we first assessed factors associated with the cumulative 
incidence of cancer overall using multivariate subdistribution hazards models as described 
by Fine and Gray.8 Adjusted subdistribution-HRs (aSHRs) were calculated from this model, 
which included terms for sex, age, race/ethnicity, and transplanted organ.
Finally, we estimated the 5-year cumulative incidence of each of the 6 cancers of interest 
(NHL, lung cancer, colorectal cancer, kidney cancer, prostate cancer, and breast cancer) 
using nonparametric competing risk methods, stratified by transplanted organ, sex, and age 
at transplantation. For strata with no cancer events, upper 95% confidence limits were 
calculated assuming a Poisson distribution for the cancer events and taking into account 
person-time at risk and the risk of competing events. For comparison, we also estimated the 
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5-year cumulative incidence of these cancers in the general US population starting at ages 
25 years, 50 years, and 75 years for men and women using data on cancer incidence and all-
cause mortality provided by the 17 cancer registries in the US Surveil-lance, Epidemiology, 
and End Results Program (available at: www.seer.cancer.gov [accessed March 7, 2013]).
All P values were 2-sided, and a P value of .05 was considered significant. All analyses 
were performed using Stata 11.0/MP for Linux (StataCorp, College Station, Tex). 
Nonparametric cumulative incidence estimates were produced using the stcompet command, 
and multivariate comparisons of cumulative incidence functions were completed using 
stcrreg.
RESULTS
There were 164,156 recipients of interest in the Transplant Cancer Match Study between 
1987 and 2008 (Table 1). Demographic characteristics of recipients were similar between 
the 2 eras (1987–1999 and 2000–2008). Most recipients were male (range, 60.2%–61.7%) 
and non-Hispanic white, although the percentage of non-Hispanic white recipients decreased 
between the eras (64.5% vs 56.3%). Transplantation recipients were older in the most recent 
era (median age, 50 years vs 45 years), and the percentage of recipients aged >60 years was 
higher in the most recent era (19.3% vs 12.5%). Kidney was the most commonly 
transplanted organ in both eras (range, 61.1%–63.2%).
In total, 8520 incident cancers arose among the transplantation recipients between 1987 and 
2008. Between the 2 eras (1987–1999 and 2000–2008), the cumulative incidence of cancer 
after transplantation increased slightly (5-year cumulative cancer incidence: 4.2% vs 4.4%, 
respectively; P = .006) (Fig. 1A). Over the same period, there was a larger decline in the 
cumulative incidence of the competing events (5-year cumulative incidence for death, graft 
failure, or retransplantation: 31.9% vs 26.6%, respectively; P < .001) (Fig. 1B). The small 
increase in the cumulative incidence of cancer was not a result of an increase in the hazard 
(instantaneous risk) of cancer (HR, 0.99; 95% confidence interval [CI], 0.94–1.04). Instead, 
the increasing cumulative incidence of cancer was related to a declining hazard of death, 
graft failure, or retransplantation between eras (HR, 0.78; 95% CI, 0.77–0.79).
Remaining analyses focused on the most recent transplantation era (2000–2008). Among the 
91,171 recipients in this era, the cumulative incidence of cancer was lower for females than 
for males (aSHR, 0.77; 95% CI, 0.72–0.83) and increased with age at transplantation 
compared with recipients ages birth to 35 years (ages 36–50 years: aSHR, 1.79 [95% CI, 
1.54–2.08]; ages 51–60 years: aSHR, 3.26 [95% CI, 2.83–3.76]; aged >60 years: aSHR, 4.61 
[95% CI, 4.00–5.31]; Ptrend < .001). Compared with kidney recipients, lung recipients had 
the highest cumulative incidence of cancer (aSHR, 1.50; 95% CI, 1.30–1.73), heart 
recipients had intermediate cumulative incidence (aSHR, 1.19; 95% CI, 1.06–1.34), and 
liver recipients were similar in cumulative incidence (aSHR, 1.01; 95% CI, 0.93–1.11).
Cumulative incidence estimates for individual cancers are presented in the figures. For NHL 
(N = 425 cases), the 5-year cumulative incidence ranged from 0.09% to 3.28% across 
categories of sex, age, and transplanted organ (Fig. 2A). Five-year cumulative incidence was 
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especially high among heart and lung recipients ages birth to 35 years (male and female 
heart recipients, 1.75%; male lung recipients, 3.28%; female lung recipients, 2.15%). It was 
also high among older lung recipients (men ages 51–60 years, 2.22%; women ages 51–60 
years, 1.70%; men aged >60 years, 1.60%). Almost all subgroups of recipients had higher 
cumulative incidence of NHL than the US general population at ages 25 and 50 years, and 
most other than kidney recipients had higher cumulative incidence of NHL than the US 
general population at age 75 years.
For lung cancer (N = 372 cases) (Fig. 2B), the 5-year cumulative incidence was 0% (or near 
0%) for recipients of all organs ages birth to 35 years, but it increased with age. Five-year 
cumulative incidence was highest among lung recipients aged >60 years (males, 3.76%; 
females, 3.87%) and female heart recipients aged >60 years (3.77%). All liver, heart, and 
lung recipients aged >35 years had 5-year cumulative incidence of lung cancer greater than 
the US general population at age 50 years (males, 0.29%; females, 0.23%), and lung 
recipients aged >50 years had 5-year cumulative incidence that was similar to or greater than 
that of those aged 75 years in the US population (males, 2.46%; females, 1.60%).
For colorectal cancer (N = 158 cases) (Fig. 3A), the 5-year cumulative incidence in 
transplantation recipients ranged from 0% in most recipients ages birth to 35 years to 1.94% 
in male lung recipients aged >60 years. Liver recipients were the only group to develop 
colorectal cancer at an age <35 years. For recipients of each type of organ, cumulative 
incidence largely increased with age. All transplantation recipients aged >50 years had 5-
year cumulative incidence at or greater than that of the US general population at the 
recommended age of screening (US males aged 50 years, 0.33%; US females aged 50 years, 
0.25%).
For kidney cancer (N = 269 cases) (Fig. 3B), 5-year cumulative incidence was highest in 
kidney recipients aged >35 years (range, 0.48%–0.84%). Five-year cumulative incidence 
was also high among some subgroups of older heart and lung recipients (range, 0.14%–
0.57%). Kidney recipients, especially those aged >35 years, had greater 5-year cumulative 
incidence of kidney cancer than observed in the US general population at any age.
For prostate cancer (N = 350 cases) (Fig. 4A), 5-year cumulative incidence was highest in 
heart recipients aged >60 years (3.65%). Recipient groups who had 5-year cumulative 
incidence similar to or greater than the general population at age 50 years (2.34%) included 
kidney, liver, and lung recipients ages 51 to 60 years or older and heart recipients ages 36 to 
50 years or older.
Results for breast cancer in females are illustrated in Figure 4B (N = 116 cases). Only heart 
recipients aged >60 years had the same or higher 5-year cumulative incidence of breast 
cancer (1.30%) as the general population at age 50 years (1.16%), which is the age cutoff 
used under 1 set of guidelines for mammography screening. Alternative recommendations 
are to start mammography screening at age 40 years in the general population. The 5-year 
cumulative incidence for women in the general population at age 40 years is 0.60%; kidney 
recipients aged >60 years (1%), and liver and heart recipients aged >50 years (range, 
0.70%–1.3%) had 5-year cumulative incidence as high or higher than this benchmark.
Hall et al. Page 5














We observed a high cumulative incidence of cancer among US solid organ recipients, with 
greater than 4% developing cancer over a 5-year period. This estimate of absolute cancer 
risk accounts for the substantial competing risks of death, graft failure, and retransplantation, 
and it corresponds to the probability that a transplantation recipient will develop cancer. Our 
results are consistent with previous Canadian and British studies, which likewise reported an 
approximately 4% to 4.8% cumulative incidence of cancer at 5 years after solid organ 
transplantation.9,10 In addition, we identified subgroups of recipients with an elevated 
cumulative incidence for preventable or screen-detectable cancers, which may help frame 
transplantation management or targeted screening protocols.
Cumulative incidence measures reflect the risk of both cancer and the competing events that 
may preclude the development of cancer. Among US recipients, we observed that the 
cumulative incidence of cancer increased slightly across 2 transplantation eras. We could 
hypothesize that this increase in cumulative incidence may be caused by changes in cancer 
risk factors or screening. If so, then we would expect those changes to translate into changes 
in the instantaneous risk for cancer (captured by the cancer-specific hazard function). 
However, the increase in cumulative incidence actually was not caused by an increase in the 
hazard of cancer but, instead, was because of a decreasing hazard for death, graft failure, or 
retransplantation. In other words, improvements in clinical management have allowed 
recipients to live longer with a functioning graft, which provides an increased opportunity to 
develop cancer. Thus, cumulative incidence is useful when considering cancer prevention or 
screening strategies, because it appropriately accommodates for competing risks. We 
observed that cumulative incidence of select cancers among subgroups of transplantation 
recipients was as high or higher than that observed in the general population at ages for 
which cancer prevention and screening are recommended.
Except for nonmelanoma skin cancer, NHL is the most common cancer after transplantation. 
NHL comprises the malignant end of the spectrum of post-transplantation 
lymphoproliferative disorders (PTLDs).11 In transplantation recipients, poor immune control 
of Epstein-Barr virus (EBV) has been linked to the high incidence of NHL and PTLDs in 
general, especially for children who experience primary EBV infection after 
transplantation.12,13 Our study revealed subgroups at par ticular risk for developing NHL. 
The 5-year cumulative incidence, as might be expected, was high among the youngest 
recipients (ages 0–35 years) for every type of transplantation. In addition, lung and heart 
recipients aged >50 years were at high risk. Lung recipients had the highest cumulative 
incidence, especially at older ages, despite high mortality experienced by this group (ie, the 
5-year survival for lung recipients aged >65 years who underwent transplantation between 
2003 and 2008 was 41.7%; 2010 Annual Data Report available at: www.srtr.org [accessed 
March 7, 2013]). The possible benefits of decreasing immunosuppression in these high-risk 
recipient populations to reduce the cumulative incidence of NHL must be weighed against 
the risk of increasing rejection rates. Some transplantation centers closely monitor EBV viral 
load in children to identify recipients at highest risk of PTLDs,14,15 although the efficacy of 
this approach is not fully established. Similar monitoring may be warranted for lung 
recipients given their high cumulative incidence of NHL.
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Lung cancer is the next most common malignancy among transplantation recipients.6 The 5-
year cumulative incidence of lung cancer was highest in heart and lung recipients, which 
may be related to smoking as a contributor to end-stage heart and lung disease. Some lung 
recipients receive only a single lung, and cancers are most often diagnosed in the remaining 
native lung, reflecting the role of underlying pulmonary disease, including inflammatory 
processes and repeated infections, in the development of lung cancer.16–18 Our results 
highlight the importance of encouraging and facilitating transplantation recipients to quit 
tobacco smoking. Given the high rate of smoking resumption after transplantation,19,20 this 
issue should be monitored longitudinally. Recent findings from the National Lung Screening 
Trial suggest that annual computed tomography scan screening is effective in reducing 
overall mortality in a population with a 5-year cumulative incidence of lung cancer of at 
least 3.6%.21 Because this level of risk is on par with what we observed in heart and lung 
transplantation recipients aged >60 years, it is possible that lung cancer screening would 
benefit this subset of the transplantation population.
Kidney cancer is most common in kidney recipients and frequently arises in the native 
kidneys in association with acquired polycystic kidney disease.22,23 However, clinical 
practice guidelines for kidney recipients do not currently include kidney cancer screening.24 
In a recent cost-effectiveness analysis of screening for kidney cancer using ultrasound,25 
Wong et al observed that the cost per life-year saved was too high to recommend screening 
for all kidney recipients. Nonetheless, screening may be cost-effective for high-risk 
subgroups of kidney recipients, such as those with acquired polycystic kidney disease, a 
family history of kidney cancer, tobacco use, or certain genetic syndromes. We observed 
that the cumulative incidence of kidney cancer among kidney recipients increased steeply at 
age 35 years, suggesting that this may be an important age threshold.
The cumulative incidence of colorectal cancer also was high after transplantation, 
particularly for older recipients. For colorectal cancer, all organ recipients aged ≥50 years 
had higher cumulative incidence than the general US population at age 50 years (the 
recommended age for colorectal cancer screening).26 Because the utility of screening largely 
depends on the expected probability of developing cancer, our findings suggest that 
transplantation recipients aged >50 years should receive standard colorectal cancer 
screening.
Prostate cancer is the second most common cancer among American men after skin cancer. 
Nearly 66% of prostate cancer is diagnosed in men aged ≥65 years, and it is rare before age 
40 years. Among transplantation recipients, there has been no demonstrated increased risk 
for prostate cancer compared with the general population.1,6 In addition, the competing risks 
of graft failure and death rise with age, which has the effect of decreasing the cumulative 
incidence of prostate cancer in older transplantation recipients. Approaches for prostate 
cancer screening include digital rectal examination and measurement of serum prostate-
specific antigen; however, there are currently no definitive recommendations for the general 
population. Given the lack of an elevated risk in transplantation recipients and uncertainties 
in the sensitivity and specificity of screening tests in this population, it is unclear whether 
prostate cancer screening for transplantation recipients is warranted.
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Breast cancer is the second most common cancer among American women, again, after skin 
cancer. Like prostate cancer in males, breast cancer risk in female transplantation recipients 
is not increased; and, in the Transplant Cancer Match Study, the risk was actually lower than 
that in the general population.6 Consequently, only heart recipients aged >60 years had 5-
year cumulative incidence at least as high as women in the general population at age 50 
years, and the 5-year cumulative incidence in recipients at age 50 years was more 
comparable to that in the general population at age 40 years. For women in the US general 
population, there is debate about whether mammography screening should begin at age 40 
years or age 50 years.27,28 For transplantation recipients, current recommendations are to 
begin screening at age 50 years.24 Although an argument could be made for this approach, 
there is a lack of data on the sensitivity and specificity of screening mammography in the 
transplantation setting.
Indeed, the question of colorectal, prostate, and breast cancer screening among 
transplantation recipients is not straight forward. The cumulative incidence of cancer, 
although important, is only part of the equation, and the decision to screen also needs to 
consider that the sensitivity and specificity of screening modalities could be reduced in the 
transplantation setting, and risks associated with screening and treatment could be increased. 
Thus, applying current screening guidelines from the general population ultimately may not 
benefit transplantation recipients.29 For instance, the benefits of colorectal cancer screening 
must be weighed against potentially increased complications of invasive screening (eg, 
colonoscopy), including those related to the high burden of cardiovascular disease and 
delayed wound healing after biopsies. In the absence of clinical trials, there may be value in 
modeling the effects of various assumptions on the benefits and costs of screening or 
prevention approaches. To make informed recommendations for this population, it will be 
necessary to study the validity of extrapolating information about screening from the general 
population to transplantation recipients, the time course over which benefits and harms 
accrue, and the efficacy of interventions to treat cancer precursor lesions and cancer itself.
Cutaneous squamous cell cancers are the most frequent cancer after transplantation, and 
recipients are at greatly increased risk for these cancers.30,31 A limitation to our study was 
the lack of data for nonmelanoma skin cancers, because cancer registries do not capture 
information on these diagnoses. Sun protection by behavior, clothing, and daily sun screen 
application are the most effective preventive measures for skin cancer.32 To prevent and 
screen for squamous cell skin cancers, a multidisciplinary approach is advocated, beginning 
with education before transplantation, yearly dermatologist inspection after transplantation, 
and proactive treatment of in situ precursor lesions, such as actinic keratosis and Bowen 
disease.33,34 These screening guidelines also help in early detection of melanoma and other 
cutaneous malignancies.
Strengths of our study include its large size and representativeness of nearly half of the US 
transplantation population. Our choice of strata based on sex, age, and transplanted organ 
addresses major demographic and clinical characteristics related to cancer risk. Nonetheless, 
estimates of cancer risk ideally should account for such factors as smoking status, etiology 
of end-stage organ disease, other underlying medical conditions (eg, ulcerative colitis, 
hepatitis C status, EBV status), and family history. Information on some of these 
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characteristics is not collected by the Scientific Registry of Transplant Recipients, and 
providing further stratification on other characteristics was beyond the scope of the current 
analyses.
In summary, our study quantified the absolute risk of cancer of solid organ transplantation 
recipients and compared this risk with the general population. We also identified some 
recipient subgroups at a high risk for specific cancers, including NHL for thoracic 
transplantation recipients at the extremes of age, lung cancer for older thoracic organ 
recipients, and kidney cancer for all but the youngest kidney recipients. These results 
suggest some avenues to target screening or prevention measures. Our results for colorectal, 
prostate, and breast cancers provide a context for considering the appropriateness of 
adapting general population screening guidelines to transplantation recipients. As the 
management of other transplantation-related conditions improves and the risk of competing 
events declines, morbidity and mortality from cancer will increase in recipients. More work 
is necessary to determine responsible prevention and screening protocols for these patients.
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The cumulative incidence of cancer and of death, graft failure, or retransplantation among 
US solid organ transplantation recipients is illustrated. Curves indicate the cumulative 
incidence of (A) all incident cancers and (B) the competing events of death, graft failure, or 
retransplantation after kidney, liver, heart, or lung transplantation. Results are provided 
separately for 2 eras defined by calendar year of transplantation. The vertical axis indicates 
the percentage of recipients with the specified outcome; the scales differ in A and B.
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The 5-year cumulative incidence of (A) non-Hodgkin lymphoma and (B) lung cancer are 
illustrated after transplantation and for the US population from 2000 to 2008. Results 
correspond to the probability that individuals will develop the specified cancer over a 5-year 
period. Estimates for recipients are limited to patients who underwent transplantation during 
2000 to 2008 and are stratified by transplanted organ, sex, and age at transplantation. 
Estimates of cumulative incidence for the US population were derived from Surveillance, 
Epidemiology, and End Results (SEER) Program data.
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The 5-year cumulative incidence of (A) colorectal cancer and (B) kidney cancer is illustrated 
after transplantation and for the US population from 2000 to 2008. Estimates for recipients 
are limited to patients who underwent transplantation during 2000 to 2008 and are stratified 
by transplanted organ, sex, and age at transplantation. Results correspond to the probability 
that individuals will develop the specified cancer over a 5-year period. Estimates of 
cumulative incidence for the US population were derived from Surveillance, Epidemiology, 
and End Results (SEER) Program data. Scales differ in A and B.
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The 5-year cumulative incidence of (A) prostate cancer and (B) breast cancer is illustrated 
after transplantation and for the US population from 2000 to 2008. Estimates for recipients 
are limited to patients who underwent transplantation during 2000 to 2008 and are stratified 
by transplanted organ and age at transplantation. Results correspond to the probability that 
individuals will develop the specified cancer over a 5-year period. Estimates of cumulative 
incidence for the US population were derived from Surveillance, Epidemiology, and End 
Results (SEER) Program data. Scales differ in A and B.
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TABLE 1
Demographic Characteristics of Transplantation Recipients in the Transplant Cancer Match Study, by Era of 
Transplantation (1987–2008)
No. of Patients (%)
Transplantation Period
All Recipients 1987–1999 2000–2008
Sex
 Male 72,985 (61) 43,959 (60.2) 56,250 (61.7)
 Female 91,171 (39) 29,026 (39.8) 34,921 (38.3)
Age at transplantation, y
 0–35 42,121 (25.7) 21,759 (29.8) 20,362 (22.3)
 36–50 51,953 (31.6) 24,984 (34.2) 26,969 (29.6)
 51–60 43,411 (26.4) 17,162 (23.5) 26,249 (28.8)
 >60 26,671 (16.3) 9080 (12.5) 17,591 (19.3)
Race/ethnicity
 Non-Hispanic white 98,363 (59.9) 47,081 (64.5) 51,282 (56.3)
 Non-Hispanic black 27,842 (17) 11,488 (15.7) 16,354 (17.9)
 Hispanic/other 36,845 (22.4) 13,988 (19.2) 22,857 (25.1)
 Missing 1106 (0.67) 428 (0.59) 678 (0.74)
Transplanted organ
 Kidney 102,106 (62.2) 44,534 (61.1) 57,572 (63.2)
 Liver 37,944 (23.1) 16,574 (22.7) 21,370 (23.4)
 Heart 17,134 (10.4) 9076 (12.4) 8058 (8.8)
 Lung 6972 (4.3) 2801 (3.8) 4171 (4.6)
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